September 2024 in “Drugs & Therapy Perspectives” Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.
3 citations
,
August 2025 in “Frontiers in Pharmacology” Oral JAK inhibitors are safe for alopecia areata, but baricitinib may cause more acne and infections.
Higher alarin levels might link hair loss and metabolic syndrome.
227 citations
,
April 2023 in “The Lancet” Ritlecitinib effectively treats alopecia areata and is well-tolerated.
1 citations
,
February 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively promotes long-term hair regrowth in alopecia areata patients.
March 2023 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.
34 citations
,
August 2002 in “British Journal of Dermatology” ALA-PDT is effective and safe for chronic X-ray dermatitis, providing complete or partial remission.
December 2025 in “The Journal of Dermatology” Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.
March 2026 in “Immunological Medicine” Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.
12 citations
,
June 2023 in “JAMA network open” JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Upadacitinib effectively treats severe alopecia areata and is safe.
January 2026 in “Skin Health and Disease” Irish dermatologists use JAK inhibitors for alopecia areata but want standardized treatment guidelines.
6 citations
,
March 2016 in “Scandinavian journal of immunology” Janus kinase inhibitors show promise in treating alopecia areata but need more safety research.
August 2023 in “International journal of research in dermatology” Janus kinase inhibitors are effective and generally safe for treating hair loss in adults with alopecia areata.
5 citations
,
April 2019 in “Journal of Investigative Dermatology” Oral JAK inhibitors improved alopecia areata by modulating immune responses and boosting hair growth.
September 2025 in “Asian journal of pediatric dermatology.” Abrocitinib helped a 14-year-old girl with severe alopecia areata regrow her hair significantly.
15 citations
,
December 2019 in “European Journal of Dermatology” Low-dose tofacitinib is effective and cheaper for severe alopecia areata.
53 citations
,
July 2018 in “Drug design, development and therapy” Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.
11 citations
,
April 2015 in “EBioMedicine” JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.
October 2024 in “Clinical Cosmetic and Investigational Dermatology” Brevilin-A is a safe and effective treatment for mild to moderate alopecia areata in children.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Baricitinib significantly improves hair regrowth in severe alopecia areata.
36 citations
,
December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
17 citations
,
January 2019 in “Journal of cutaneous medicine and surgery” JAK inhibitors show promise for treating hair loss in alopecia areata but need more clinical trials to confirm safety and effectiveness.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
5 citations
,
October 2024 in “Reumatismo” Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.
6 citations
,
February 2023 in “Journal of the American Academy of Dermatology” Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.
2 citations
,
September 2024 in “Internal Medicine Journal” Upadacitinib helped regrow hair and maintain ulcerative colitis remission.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Ritlecitinib effectively regrows and maintains scalp, eyebrow, and eyelash hair in alopecia areata patients.
3 citations
,
June 1983 in “Archives of Dermatology” Aminopterin effectively improves skin conditions but has toxic side effects that need careful monitoring.